Invitation to attend a live Elekta Unity treatment at University Hospital Tübingen

STOCKHOLM, October 24, 2019 – Elekta (EKTA-B.ST) invites financial analysts and investors to Tübingen on November 29 for an update on the use of Elekta Unity and a better understanding of the clinical possibilities of the MR-Linac.

Based on the delivery of 1,400 fractions and treating almost 100 patients with Elekta Unity, Prof. Dr. Daniel Zips, Medical Director of Department of Radiation Oncology, University Hospital Tübingen & Director of Comprehensive Cancer Center Tübingen-Stuttgart, will present his experience with the MR-Linac. Participants will also view a live treatment fraction using Elekta Unity, with commentary by Prof. Dr. Zips.

In addition, Kevin Brown, Distinguished Scientist at Elekta, will give a scientific update of the latest learnings from Elekta Unity, while CEO, Dr. Richard Hausmann, and CFO, Gustaf Salford, will discuss the company’s latest development based on the second quarter report published on November 28.

The invitation is on a first-come, first-served basis, with a limit of 50 participants. If you wish to attend, please register using this link: http://www.cvent.com/d/qhqldh

# # # 

For further information, please contact:
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time 

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.